Source: The Wall Street Journal (paywall)
Enterprise buyers are systematically mixing cheaper inference from Chinese models (DeepSeek, etc.) with premium reasoning from OpenAI and Anthropic—a deliberate cost-arbitrage strategy that fractures the "all-in" vendor lock-in the American labs were pricing into their IPO multiples. Procurement teams now treat model selection as a commodity sourcing problem rather than a strategic platform choice, directly undermining the unit economics that justified $80B+ valuations for labs betting on token consumption growth.